Cargando…

The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017

BACKGROUND: Considering the growing prevalence of chronic disease and diabetes mellitus (DM) in Belgium, alongside population aging, insight into the economic burden of DM is essential for decision makers. To the best of our knowledge, there is no research on the subject in Belgium. Thus, our aim wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinheiro, V, Gorasso, V, Devleesschauwer, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835036/
http://dx.doi.org/10.1093/eurpub/ckac131.146
_version_ 1784868590617362432
author Pinheiro, V
Gorasso, V
Devleesschauwer, B
author_facet Pinheiro, V
Gorasso, V
Devleesschauwer, B
author_sort Pinheiro, V
collection PubMed
description BACKGROUND: Considering the growing prevalence of chronic disease and diabetes mellitus (DM) in Belgium, alongside population aging, insight into the economic burden of DM is essential for decision makers. To the best of our knowledge, there is no research on the subject in Belgium. Thus, our aim was to estimate the direct and indirect costs associated to DM in Belgium between 2013 and 2017. METHODS: On a first phase, we performed a retrospective observational study, calculating the direct (i.e., ambulatory care, hospitalizations and medications) and indirect (work absenteeism, by multiplying mean daily wage and days absent from work) costs in the Belgian population with DM in 2013-2017. Data was retrieved from the Belgian Intermutualistic Agency (which manages compulsory health insurance) database and the Belgian Health Interview Survey database, namely DM prevalence, healthcare costs, days absent from work and sociodemographic and health factors. Subsequently, negative binomial regression models were used to assess the association of mean yearly costs to DM and adjustments for age, education level, physical activity, sugared drink consumption and body-mass index were included. Mean incremental costs were estimated through recycled predictions, considering the observed DM prevalence in Belgium in the study period and a counterfactual scenario with null prevalence. RESULTS: We found a direct mean yearly incremental cost of €2 477 per DM patient, in Belgium, associated with age, low educational level and low physical activity. In the total Belgian population, the total yearly incremental healthcare cost of DM was €1.5 billion. Indirect yearly incremental cost of DM resulted to be not significantly different from the population without DM. CONCLUSIONS: DM has a major economic burden in Belgium, one that is expected to continue to rise in the future, alongside population aging. These results are essential for health planning and resource allocation. KEY MESSAGES: • DM has a major economic burden in Belgium, especially when it comes to direct health expenditures with ambulatory care, hospitalizations and medications. • Considering the growing prevalence of DM and population aging, these results are essential for health planning and resource allocation.
format Online
Article
Text
id pubmed-9835036
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98350362023-01-17 The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017 Pinheiro, V Gorasso, V Devleesschauwer, B Eur J Public Health Poster Displays BACKGROUND: Considering the growing prevalence of chronic disease and diabetes mellitus (DM) in Belgium, alongside population aging, insight into the economic burden of DM is essential for decision makers. To the best of our knowledge, there is no research on the subject in Belgium. Thus, our aim was to estimate the direct and indirect costs associated to DM in Belgium between 2013 and 2017. METHODS: On a first phase, we performed a retrospective observational study, calculating the direct (i.e., ambulatory care, hospitalizations and medications) and indirect (work absenteeism, by multiplying mean daily wage and days absent from work) costs in the Belgian population with DM in 2013-2017. Data was retrieved from the Belgian Intermutualistic Agency (which manages compulsory health insurance) database and the Belgian Health Interview Survey database, namely DM prevalence, healthcare costs, days absent from work and sociodemographic and health factors. Subsequently, negative binomial regression models were used to assess the association of mean yearly costs to DM and adjustments for age, education level, physical activity, sugared drink consumption and body-mass index were included. Mean incremental costs were estimated through recycled predictions, considering the observed DM prevalence in Belgium in the study period and a counterfactual scenario with null prevalence. RESULTS: We found a direct mean yearly incremental cost of €2 477 per DM patient, in Belgium, associated with age, low educational level and low physical activity. In the total Belgian population, the total yearly incremental healthcare cost of DM was €1.5 billion. Indirect yearly incremental cost of DM resulted to be not significantly different from the population without DM. CONCLUSIONS: DM has a major economic burden in Belgium, one that is expected to continue to rise in the future, alongside population aging. These results are essential for health planning and resource allocation. KEY MESSAGES: • DM has a major economic burden in Belgium, especially when it comes to direct health expenditures with ambulatory care, hospitalizations and medications. • Considering the growing prevalence of DM and population aging, these results are essential for health planning and resource allocation. Oxford University Press 2022-10-25 /pmc/articles/PMC9835036/ http://dx.doi.org/10.1093/eurpub/ckac131.146 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Displays
Pinheiro, V
Gorasso, V
Devleesschauwer, B
The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017
title The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017
title_full The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017
title_fullStr The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017
title_full_unstemmed The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017
title_short The economic burden of Diabetes Mellitus in Belgium from 2013 to 2017
title_sort economic burden of diabetes mellitus in belgium from 2013 to 2017
topic Poster Displays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835036/
http://dx.doi.org/10.1093/eurpub/ckac131.146
work_keys_str_mv AT pinheirov theeconomicburdenofdiabetesmellitusinbelgiumfrom2013to2017
AT gorassov theeconomicburdenofdiabetesmellitusinbelgiumfrom2013to2017
AT devleesschauwerb theeconomicburdenofdiabetesmellitusinbelgiumfrom2013to2017
AT pinheirov economicburdenofdiabetesmellitusinbelgiumfrom2013to2017
AT gorassov economicburdenofdiabetesmellitusinbelgiumfrom2013to2017
AT devleesschauwerb economicburdenofdiabetesmellitusinbelgiumfrom2013to2017